Cetuximab联合放疗或化疗治疗11例头颈恶性肿瘤近期疗效分析  

Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer:a report of 11 cases

作　　者：夏良平[1,2] 张蓓[1,2] 刘茂珍[1,2] 胡丕丽[1,2] 陈徐贤[1,2] 郭桂芳[1,2] 丘惠娟[1,2] 戎煜明[1,2] 钱穗毅[1,2] 周菲菲[1,2] 黄圆圆[1,2] 汪桃利[1,2] 

机构地区：[1]华南肿瘤学国家重点实验室,广东广州510060 [2]中山大学肿瘤防治中心综合科,广东广州510060

出　　处：《癌症》2009年第9期977-982,共6页Chinese Journal of Cancer

基　　金："重大新药创新"科技重大专项基金(No.2008ZX09312-002)~~

摘　　要：背景与目的:Cetuximab联合放疗或化疗治疗头颈恶性肿瘤的报道不多。本研究总结Cetuximab与放疗或化疗联合治疗头颈恶性肿瘤的近期疗效。方法:选取2005年10月1日至2008年9月30日在中山大学肿瘤防治中心,采用Cetuximab与放疗联合治疗(联合放疗组)的6例,及采用Cetuximab与化疗联合治疗(联合化疗组)的5例头颈恶性肿瘤患者,回顾性分析其近期治疗效果和安全性。结果:共计完成82个Cetuximab治疗周期(中位周期数是7),没有因为Cetuximab毒性而停止治疗的患者,没有治疗相关死亡。联合放疗组中4例达到了完全缓解(complete remission,CR),2例部分缓解(partial remission,PR)。4例CR者都有痤疮样皮疹,3例为Ⅲ度以上。而2例PR者有1例Ⅰ度皮疹。5例Cetuximab同期放化疗者都有放射野皮肤反应,4例为Ⅲ度以上。放疗组的血液学毒性除1例为Ⅳ度外,其他5例都比较轻。联合化疗组5例中PR、SD(疾病稳定,stable disease)和PD(疾病进展,progressed disease)分别有2例、2例和1例。联合化疗组的皮疹发生率不高,Ⅲ度以上骨髓抑制有3例。结论:Cetuximab与放疗联合效果较好,但放射野皮肤反应比较大;Cetuximab和化疗联合也是晚期头颈肿瘤的有效选择之一。Cetuximab在中国人头颈肿瘤中的有效性和安全性需要积累更多的资料。Background and Objective： Cetuximab combined with radiotherapy or chemotherapy has been used to treat head and neck cancer in recent years, but few reports are available in China now. This study was to summarize our experiences in treating patients with head and neck cancer cetuximab. Methods. From October 1st, 2005 to September 30th, 2008, six with patients heacl and neck cancer were treated using cetuximab combined with radiotherapy and five were treated using cetuximab combined with chemotherapy in Sun Yat-sen University Cancer Center. The short-term efficacy and safety were analyzed. Results： A total of 82 cycles of cetuximab treatment, with a median of seven cycles, were administered safely. There was no treatment-associated death and no cetuximab-associated discontinuation. In cetuximab combined with radiotherapy group, four patients achieved complete response （CR） and two achieved partial response （PR）; all CR patients had hadacne-like rash （three cases were ≥ grade Ⅲ ）, only one PR patient had grade Ⅰ rash; five patients had skin reaction in the irradiation field （four cases of skin reaction were ≥grade Ⅲ ）; hematological toxicity was slight excepted one case of grade Ⅳ. In cetuximab combined chemotherapy group, two patients achieved PR, two had stable disease （SD） and one had progressed disease （PD）; the of acne-like rash was low, and three patients experienced bone marrow depression above grade Ⅲ. Conclusion： Cetuximab combined wthe either radiotherapy or chemotherapy are good options for suitable patients with head and neck cancer.

关 键 词：CETUXIMAB 头颈肿瘤 放射治疗 化学治疗 有效率 副反应 

分 类 号：R739.91[医药卫生—肿瘤]